Sunggoro Agus Jati, Dwianingsih Ery Kus, Utomo Bambang Purwanto, Purwanto Ibnu
Hematology and Medical Oncology Division, Internal Medicine Department, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University/Dr. Sardjito Hospital, Yogyakarta, Indonesia.
Hematology and Medical Oncology Division, Internal Medicine Department, Faculty of Medicine, Sebelas Maret University/Dr. Moewardi Hospital, Surakarta, Indonesia.
Case Rep Oncol. 2021 Mar 2;14(1):262-268. doi: 10.1159/000512826. eCollection 2021 Jan-Apr.
Gastrointestinal lymphoma accounts for up to 20% of all extranodal lymphoma cases. Among them, the ileum is the second most commonly affected site after the stomach. The majority of gastrointestinal lymphoma originates from the B cell lineage. We report the case of 60-year-old male with persistent anemia, hematochezia, and poor performance status (PS). After thorough workup, imaging, and pathological study, the patient was diagnosed with diffuse large B-cell lymphoma of the terminal ileum. He was treated with R-CHOP based chemotherapy with dose tailoring to accommodate his poor PS. His symptoms promptly subsided after the first chemotherapy cycle. After eight cycles of chemotherapy, terminal ileum wall thickening was gone and the patient was disease-free for 6 months. This case report shows that chemotherapy can be beneficial in patients with gastrointestinal lymphoma despite poor PS. Therefore, it should be given when possible with proper dose tailoring.
胃肠道淋巴瘤占所有结外淋巴瘤病例的20%。其中,回肠是仅次于胃的第二常见受累部位。大多数胃肠道淋巴瘤起源于B细胞系。我们报告一例60岁男性,有持续性贫血、便血和较差的体能状态(PS)。经过全面检查、影像学和病理研究,该患者被诊断为回肠末端弥漫性大B细胞淋巴瘤。他接受了基于R-CHOP的化疗,并根据其较差的PS调整剂量。第一个化疗周期后,他的症状迅速缓解。经过八个周期的化疗,回肠壁增厚消失,患者无病生存6个月。本病例报告表明,尽管PS较差,化疗对胃肠道淋巴瘤患者仍可能有益。因此,应尽可能给予适当剂量调整的化疗。